|
시장보고서
상품코드
2152387
디지털 PCR 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 기술별, 용도별, 최종 용도별, 지역별 및 부문별 전망(2026-2033년)Digital PCR Market Size, Share & Trends Analysis Report By Product (Instruments & Systems, Reagents & Consumables, Software & Services), By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
디지털 PCR 시장 요약
세계 디지털 PCR 시장 규모는 2025년 13억 달러로 평가되었고, 2026년 15억 달러에서 2033년까지 41억 달러로 확대되어 2026-2033년 연평균 성장률(CAGR) 15.2%를 기록할 것으로 예측됩니다.
북미가 시장을 주도하고 있으며, 2025년에는 매출 점유율의 41.2%를 차지했습니다. 시장 성장은 주로 정밀 의학 및 분자진단의 보급에 의해 주도되고 있으며, 디지털 PCR은 핵산의 고감도 및 절대 정량, 희귀 변이 검출, 미세 잔류 병변 평가, 그리고 복제수 변이 분석에 점점 더 많이 활용되고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법 및 범위
제2장 요약
제3장 세계 디지털 PCR 시장 : 변수, 동향, 범위
- 시장 전망
- 시장 역학
- 세계 디지털 PCR 시장 분석 도구
제4장 세계 디지털 PCR 시장 : 제품별 추정 및 동향 분석
- 세계 디지털 PCR 시장 : 제품별 동향 분석
- 세계 디지털 PCR 시장 : 제품별 규모 및 동향 분석, 2021년-2033년
- 장비·시스템
- 시약 및 소모품
- 소프트웨어 및 서비스
제5장 세계 디지털 PCR 시장 : 기술별 추정 및 동향 분석
- 세계 디지털 PCR 시장 : 기술별 동향 분석
- 세계 디지털 PCR 시장 : 기술별 규모 및 동향 분석, 2021년-2033년
- 드롭렛 방식의 dPCR
- 칩/챔버형 dPCR
제6장 세계 디지털 PCR 시장 : 용도별 추정 및 동향 분석
- 세계 디지털 PCR 시장 : 용도별 동향 분석
- 세계 디지털 PCR 시장 : 용도별 규모 및 동향 분석, 2021년-2033년
- 연구
- 임상 진단
- 바이오제약
- 환경 및 기타 분석
제7장 세계 디지털 PCR 시장 : 최종 용도별 추정 및 동향 분석
- 세계 디지털 PCR 시장 : 최종 용도별 동향 분석
- 세계 디지털 PCR 시장 : 최종 용도별 규모 및 동향 분석, 2021년-2033년
- 학술 연구 기관
- 병원 및 진단실험실
- 제약 및 생명공학 기업
- CRO 및 CDMO
- 기타
제8장 디지털 PCR 시장 : 지역별 추정 및 동향 분석
- 지역별 대시보드
- 시장 규모·전망 및 동향 분석, 2021년-2033년
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
- 아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
- 라틴아메리카
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트
제9장 경쟁 현황
- 기업 및 경쟁사 분류
- 전략 매핑
- 기업 점유율 분석, 2025년
- 주요 인증 기관/인증 제도 운영 단체 목록
- 기업 프로파일 목록
- Bio-Rad Laboratories Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Standard BioTools Inc.
- Stilla Technologies.
- JN Medsys
- Combinati Inc.
- Sysmex Corporation
- Takara Bio Inc.
Digital PCR Market Summary
The global digital PCR market size was valued at USD 1.3 billion in 2025 and is projected to grow from USD 1.5 billion in 2026 to USD 4.1 billion by 2033, growing at a CAGR of 15.2% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 41.2% in 2025. Market growth is primarily driven by the growing adoption of precision medicine and molecular diagnostics, where digital PCR is increasingly used for highly sensitive and absolute quantification of nucleic acids, rare mutation detection, minimal residual disease assessment, and copy number variation analysis.
Global Digital PCR Market Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the digital PCR market report on the basis of product, technology, application, end use, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Instruments & Systems
- Reagents & Consumables
- Software & Services
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Droplet-based dPCR
- Chip/Chamber-based dPCR
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Research
- Clinical Diagnostics
- Biopharma
- Environmental & Other Testing
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Academic & Research Institutes
- Hospitals & Diagnostic Labs
- Pharma & Biotech Companies
- CROs & CDMOs
- Others
- Regional Outlook (Revenue, USD Million; 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Norway
- Denmark
- Sweden
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Product Segment
- 1.2.2. Technology Segment
- 1.2.3. Application Segment
- 1.2.4. End use Segment
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
Chapter 3. Global Digital PCR (dPCR) Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Growing Adoption of Precision Medicine and Molecular Diagnostics
- 3.2.1.2. Expansion of Cell and Gene Therapy Development
- 3.2.1.3. Increasing Investments in Genomics Research and Life Science Innovation
- 3.2.2. Market restraint analysis
- 3.2.2.1. High Capital Investment and Operating Costs
- 3.2.2.2. Complex Regulatory and Clinical Validation Requirements
- 3.2.3. Market opportunity analysis
- 3.2.1. Market driver analysis
- 3.3. Global Digital PCR (dPCR) Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.2. PESTLE Analysis
Chapter 4. Global Digital PCR (dPCR) Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Digital PCR (dPCR) Market Product Movement Analysis
- 4.3. Global Digital PCR (dPCR) Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Instruments & Systems
- 4.4.1. Instruments & Systems market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5. Reagents & Consumables
- 4.5.1. Reagents & Consumables market estimates and forecasts 2021 to 2033 (USD Million)
- 4.6. Software & Services
- 4.6.1. Software & Services market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Global Digital PCR (dPCR) Market: Technology Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Digital PCR (dPCR) Market Technology Movement Analysis
- 5.3. Global Digital PCR (dPCR) Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
- 5.4. Droplet-based dPCR
- 5.4.1. Droplet-based dPCR market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5. Chip/Chamber-based dPCR
- 5.5.1. Chip/Chamber-based dPCR market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Global Digital PCR (dPCR) Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Digital PCR (dPCR) Market Application Movement Analysis
- 6.2.1. Global Digital PCR (dPCR) Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 6.3. Research
- 6.3.1. Research market estimates and forecasts 2021 to 2033 (USD Million)
- 6.4. Clinical Diagnostics
- 6.4.1. Clinical Diagnostics market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5. Biopharma
- 6.5.1. Biopharma market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6. Environmental & Other Testing
- 6.6.1. Environmental & Other Testing market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Global Digital PCR (dPCR) Market: End-use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Digital PCR (dPCR) Market End-use Movement Analysis
- 7.2.1. Global Digital PCR (dPCR) Market Size & Trend Analysis, by End-use, 2021 to 2033 (USD Million)
- 7.3. Academic & Research Institutes
- 7.3.1. Academic & Research Institutes market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4. Hospitals & Diagnostic Labs
- 7.4.1. Hospitals & Diagnostic Labs market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5. Pharma & Biotech Companies
- 7.5.1. Pharma & Biotech Companies market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6. CROs & CDMOs
- 7.6.1. CROs & CDMOs market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7. Others
- 7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Digital PCR (dPCR) Market: Regional Estimates & Trend Analysis
- 8.1. Regional Dashboard
- 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 8.3. North America
- 8.3.1. U.S.
- 8.3.1.1. Key country dynamics
- 8.3.1.2. Regulatory framework/ reimbursement structure
- 8.3.1.3. Competitive scenario
- 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.2. Canada
- 8.3.2.1. Key country dynamics
- 8.3.2.2. Regulatory framework/ reimbursement structure
- 8.3.2.3. Competitive scenario
- 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.3. Mexico
- 8.3.3.1. Key country dynamics
- 8.3.3.2. Regulatory framework/ reimbursement structure
- 8.3.3.3. Competitive scenario
- 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.1. U.S.
- 8.4. Europe
- 8.4.1. UK
- 8.4.1.1. Key country dynamics
- 8.4.1.2. Regulatory framework/ reimbursement structure
- 8.4.1.3. Competitive scenario
- 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.2. Germany
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Regulatory framework/ reimbursement structure
- 8.4.2.3. Competitive scenario
- 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.3. France
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Regulatory framework/ reimbursement structure
- 8.4.3.3. Competitive scenario
- 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.4. Italy
- 8.4.4.1. Key country dynamics
- 8.4.4.2. Regulatory framework/ reimbursement structure
- 8.4.4.3. Competitive scenario
- 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.5. Spain
- 8.4.5.1. Key country dynamics
- 8.4.5.2. Regulatory framework/ reimbursement structure
- 8.4.5.3. Competitive scenario
- 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.6. Norway
- 8.4.6.1. Key country dynamics
- 8.4.6.2. Regulatory framework/ reimbursement structure
- 8.4.6.3. Competitive scenario
- 8.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.7. Sweden
- 8.4.7.1. Key country dynamics
- 8.4.7.2. Regulatory framework/ reimbursement structure
- 8.4.7.3. Competitive scenario
- 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.8. Denmark
- 8.4.8.1. Key country dynamics
- 8.4.8.2. Regulatory framework/ reimbursement structure
- 8.4.8.3. Competitive scenario
- 8.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.1. UK
- 8.5. Asia Pacific
- 8.5.1. Japan
- 8.5.1.1. Key country dynamics
- 8.5.1.2. Regulatory framework/ reimbursement structure
- 8.5.1.3. Competitive scenario
- 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.2. China
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Regulatory framework/ reimbursement structure
- 8.5.2.3. Competitive scenario
- 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.3. India
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Regulatory framework/ reimbursement structure
- 8.5.3.3. Competitive scenario
- 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.4. Australia
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Regulatory framework/ reimbursement structure
- 8.5.4.3. Competitive scenario
- 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.5. South Korea
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Regulatory framework/ reimbursement structure
- 8.5.5.3. Competitive scenario
- 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.6. Thailand
- 8.5.6.1. Key country dynamics
- 8.5.6.2. Regulatory framework/ reimbursement structure
- 8.5.6.3. Competitive scenario
- 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.1. Japan
- 8.6. Latin America
- 8.6.1. Brazil
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Regulatory framework/ reimbursement structure
- 8.6.1.3. Competitive scenario
- 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.2. Argentina
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Regulatory framework/ reimbursement structure
- 8.6.2.3. Competitive scenario
- 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.1. Brazil
- 8.7. MEA
- 8.7.1. South Africa
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Regulatory framework/ reimbursement structure
- 8.7.1.3. Competitive scenario
- 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.2. Saudi Arabia
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Regulatory framework/ reimbursement structure
- 8.7.2.3. Competitive scenario
- 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.3. UAE
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Regulatory framework/ reimbursement structure
- 8.7.3.3. Competitive scenario
- 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.4. Kuwait
- 8.7.4.1. Key country dynamics
- 8.7.4.2. Regulatory framework/ reimbursement structure
- 8.7.4.3. Competitive scenario
- 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.1. South Africa
Chapter 9. Competitive Landscape
- 9.1. Company/Competition Categorization
- 9.2. Strategy Mapping
- 9.3. Company Market Share Analysis, 2025
- 9.4. List of Key Certification Providers/Scheme Owners
- 9.5. Company Profiles/Listing
- 9.5.1. Bio-Rad Laboratories Inc.
- 9.5.1.1. Company overview
- 9.5.1.2. Financial performance
- 9.5.1.3. Product benchmarking
- 9.5.1.4. Strategic initiatives
- 9.5.2. Thermo Fisher Scientific Inc.
- 9.5.2.1. Company overview
- 9.5.2.2. Financial performance
- 9.5.2.3. Product benchmarking
- 9.5.2.4. Strategic initiatives
- 9.5.3. QIAGEN N.V.
- 9.5.3.1. Company overview
- 9.5.3.2. Financial performance
- 9.5.3.3. Product benchmarking
- 9.5.3.4. Strategic initiatives
- 9.5.4. Standard BioTools Inc.
- 9.5.4.1. Company overview
- 9.5.4.2. Financial performance
- 9.5.4.3. Product benchmarking
- 9.5.4.4. Strategic initiatives
- 9.5.5. Stilla Technologies.
- 9.5.5.1. Company overview
- 9.5.5.2. Financial performance
- 9.5.5.3. Product benchmarking
- 9.5.5.4. Strategic initiatives
- 9.5.6. JN Medsys
- 9.5.6.1. Company overview
- 9.5.6.2. Financial performance
- 9.5.6.3. Product benchmarking
- 9.5.6.4. Strategic initiatives
- 9.5.7. Combinati Inc.
- 9.5.7.1. Company overview
- 9.5.7.2. Financial performance
- 9.5.7.3. Product benchmarking
- 9.5.7.4. Strategic initiatives
- 9.5.8. Sysmex Corporation
- 9.5.8.1. Company overview
- 9.5.8.2. Financial performance
- 9.5.8.3. Product benchmarking
- 9.5.8.4. Strategic initiatives
- 9.5.9. Takara Bio Inc.
- 9.5.9.1. Company overview
- 9.5.9.2. Financial performance
- 9.5.9.3. Product benchmarking
- 9.5.9.4. Strategic initiatives
- 9.5.1. Bio-Rad Laboratories Inc.
